Ligand validation:5OLO

OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate

OLC is a Ligand Of Interest in 5OLO designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5OLO_OLC_A_1219	10%	52%	0.324	0.829	0.96	0.91	1	1	4	0	100%	1
5OLO_OLC_A_1216	9%	43%	0.312	0.863	1.16	1.06	1	1	0	0	64%	0.64
5OLO_OLC_A_1215	7%	45%	0.307	0.818	1.17	0.97	1	1	2	0	68%	0.68
5OLO_OLC_A_1220	7%	53%	0.401	0.853	0.92	0.9	1	1	2	0	100%	1
5OLO_OLC_A_1221	6%	53%	0.361	0.798	0.98	0.86	1	1	2	0	96%	0.96
5OLO_OLC_A_1217	4%	46%	0.342	0.767	1.11	0.98	1	1	2	0	72%	0.72
5OLO_OLC_A_1222	4%	54%	0.409	0.803	0.97	0.82	1	1	0	0	88%	0.88
5OLO_OLC_A_1218	1%	42%	0.43	0.668	1.13	1.14	1	2	0	0	68%	0.68
5IU4_OLC_A_2429	61%	59%	0.136	0.926	0.8	0.78	2	1	1	0	100%	1
5OLZ_OLC_A_1225	40%	44%	0.174	0.884	0.89	1.28	1	2	8	0	100%	1
5MZJ_OLC_A_2430	38%	62%	0.16	0.876	0.68	0.79	-	-	3	0	92%	0.92
6GT3_OLC_A_2422	38%	22%	0.167	0.933	0.99	2.24	1	5	2	1	64%	0.64
5OM4_OLC_A_1227	37%	44%	0.201	0.899	0.87	1.27	1	2	6	0	100%	1
7Z0C_OLC_A_803	63%	52%	0.097	0.892	0.82	1.04	1	2	2	0	100%	1
4N6H_OLC_A_1222	63%	56%	0.117	0.932	0.81	0.87	1	1	0	0	88%	0.88
6G7H_OLC_A_310	61%	92%	0.117	0.905	0.26	0.26	-	-	0	0	100%	1
7B0O_OLC_A_302	59%	54%	0.146	0.929	0.69	1.07	1	1	2	0	100%	1
7Z09_OLC_A_824	33%	39%	0.1	0.865	1.14	1.22	2	1	0	0	52%	0.52

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.